Goldenwell Biotech, Inc.
GWLL
$3.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 62,200.00% | 7,360.00% | -114.29% | -94.74% | -95.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62,200.00% | 7,360.00% | -114.29% | -94.74% | -95.24% |
| Cost of Revenue | -150.00% | -125.00% | -100.00% | -100.00% | -80.00% |
| Gross Profit | 20,900.00% | 37,500.00% | 100.00% | -100.00% | -130.00% |
| SG&A Expenses | 4.77% | -14.33% | 8.18% | 0.43% | -88.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.51% | -14.66% | 7.70% | -0.59% | -88.46% |
| Operating Income | 48.60% | 42.76% | -8.09% | -0.95% | 88.44% |
| Income Before Tax | 40.11% | 34.50% | -17.41% | -12.10% | 87.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.11% | 34.50% | -17.41% | -12.10% | 87.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.11% | 34.50% | -17.41% | -12.10% | 87.66% |
| EBIT | 48.60% | 42.76% | -8.09% | -0.95% | 88.44% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 33.33% | 35.71% | -8.33% | -8.33% | 86.96% |
| Normalized Basic EPS | 28.57% | 37.50% | -14.29% | -14.29% | 87.72% |
| EPS Diluted | 33.33% | 35.71% | -8.33% | -8.33% | 86.96% |
| Normalized Diluted EPS | 28.57% | 37.50% | -14.29% | -14.29% | 87.72% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.65% | -0.62% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.65% | -0.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |